Prenatal DHA and Neurofunctional Development (PANDA)
The PANDA trial is a randomized clinical trial that will test 2 different doses of docosahexaenoic acid (DHA) supplementation during pregnancy on fetal and infant neurodevelopmental outcomes (autonomic development and brain function). (Registered at ClinicalTrials.gov NCT02709239). Pregnant women will be allocated to either 200 mg or 800 mg/day DHA capsules. Blood samples will be collected at enrollment, 32 weeks and at delivery, including newborn cord blood. At 32 and 36 weeks gestational age, fetal biomagnetometry will be used to obtain non-invasive measures of fetal cardiac signals, body movements and behaviors. Brain function will be measured using high-density EEG at 1, 6 and 12 months of age. Cognitive behavioral assessments will occur at 4 and 6 months of age.